Invitrogen acquires CellzDirect
Invitrogen, a provider of life science technologies for research, production and diagnostics, has announced a definitive agreement to purchase privately held American company CellzDirect for around $57 million.
CellzDirect provides hepatocyte-based cell products and related services used in the testing of new drugs. Primary human hepatocytes are the most accepted model for predicting a compound’s effects on enzymatic metabolism in the liver. Their products are mainly used by pharmaceutical and biotech companies in research and development.
“CellzDirect’s high-value products and services will greatly complement Invitrogen’s market-leading portfolio of complete cell systems, including primary cells, media, matrices and growth factors,” said Greg Lucier, Invitrogen’s chairman and CEO.
“The purchase of CellzDirect follows our strategy of investing in high growth areas of the market, specifically specialty cell systems.”
DKSH brings Bioyond Robotics' lab automation products Down Under
DKSH will provide distribution of the Bioyond Robotics portfolio of AI-driven autonomous...
Immunologist wins GSK Award for respiratory virus research
Award winner Professor Katherine Kedzierska seeks to answer an important question: why do some...
ATSE names Jane O'Dwyer as its new CEO
O'Dwyer is an executive leader with more than 30 years' experience across higher...
